Chemically reactive metabolites (CRMs) can initiate serious adverse drug reactions. In their Review, Park and colleagues discuss current approaches for the evaluation of CRMs and examine how this knowledge can inform the various stages of the drug discovery and development process.
- B. Kevin Park
- Alan Boobis
- Thomas A. Baillie